伊瓦布拉丁,心房动和中风:综合元分析和FAERS不成比例性分析
Alberto Spadotto1,2, Michele Fusaroli3, Maria Carelli1
1Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Frontiers in pharmacology
|December 5, 2025
概括
伊瓦布拉丁可能会增加心房动 (AF) 的诊断,而不是引起它. 这可能导致更早的治疗和降低中风风险,但需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 以前的研究表明,伊瓦布拉丁的使用与心房 (AF) 发生率的增加有关.
- 确切的原因尚不清楚:直接的药物效应与由于更大的心率差异而增强的AF检测.
- 早期的AF诊断可能会通过及时的抗凝剂预防来减少脑血管事件.
研究的目的:
- 调查伊瓦布拉丁与心房动 (AF) 之间的关联.
- 为了区分 ivabradine 直接导致 AF 和增加检测.
- 评估对脑血管事件风险的影响.
主要方法:
- 进行了现有文献的元分析,比较缺血性脑血管事件和AF.
- 对疑似药物不良反应的个体病例安全报告 (FAERS) 进行了不成比例分析.
- 在不成比例性分析中,包括β-阻断剂作为对照组.
主要成果:
- 对3项符合条件的研究的元分析显示,IVABRADINE与安慰剂相比,缺血性脑血管事件与AF的比率较低 (RR 0.74).
- 在FAERS中,AF在艾瓦布拉丁和β-阻断剂的使用中报告不成比例.
- 缺血性脑血管事件不成比例地仅与β-阻断剂一起报告.
结论:
- 研究结果表明,伊瓦布拉丁可能有助于增加AF诊断,而不是直接引起它.
- 需要进行进一步的前性研究,并进行持续的心电图监测.
- 澄清 ivabradine,AF 识别和脑血管风险之间的关系至关重要.
相关概念视频
Acute Coronary Syndrome III: Diagnostic Studies
199
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
199
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K


